Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2019

Open Access 01-12-2019 | Azathioprine | Case report

Crohn’s disease in a developing African mission hospital: a case report

Author: Bamidele Johnson Alegbeleye

Published in: Journal of Medical Case Reports | Issue 1/2019

Login to get access

Abstract

Background

A case is reported of innocuous intestinal obstruction requiring surgical intervention that was confirmed to be Crohn’s disease histopathologically in a resource-constrained rural mission hospital in Cameroon.

Case presentation

A 70-year man of Kumbo origin from Northwest region of Cameroon with a history of crampy right lower-quadrant abdominal pain, non-bloody, non-mucoid diarrhea alternating with constipation presented to my institution. Abdominal examination of the patient revealed an ill-defined mass in the right iliac fossa and visible peristalsis. An abdominal computed tomographic scan and barium enema study confirmed a complex ascending colonic and cecal tumor. The patient underwent exploratory laparotomy. The intraoperative finding was a huge complex inflammatory mass involving the cecum, terminal ileum, and sigmoid colon. He subsequently had sigmoidectomy with end–to-end sigmoidorectal anastomosis and a cecal resection, and the proximal ascending colon was exteriorized because end mucoid fistula and terminal ileostomy were performed. The histopathological diagnosis confirmed Crohn’s disease. The patient subsequently received five courses of adjuvant chemotherapy consisting of azathioprine, methotrexate, mesalamine, and methylprednisolone. He had complete disease remission and subsequently had closure of ileostomy with satisfactory postoperative status. The most recent follow-up abdominal computed tomographic scan and colonoscopy revealed disease-free status. The patient is also currently receiving a maintenance dose of rectal mesalamine and oral omeprazole treatment. He has been followed every 2 months in the surgical outpatient clinic over the last 16 months with satisfactory clinical outcome.

Conclusions

Crohn’s disease is uncommon in Africa, and this entity is encountered sparingly. The signs and symptoms of Crohn’s disease overlap with many other abdominal disorders, such as tuberculosis, ulcerative colitis, irritable bowel syndrome, and others. Several publications in the literature describe that it is difficult to make an accurate diagnosis of this disease, despite the fact that many diagnostic armamentaria are available to suggest its presence. Most of the patients with Crohn’s disease are treated conservatively, and a few may require surgical intervention, especially those presenting with complications such as intestinal obstruction, perforations, and abscess as well as fistula formations, as seen in this index patient. Crohn’s disease is considered by many to be a very rare disease in Africa. It is interesting to know that Crohn’s disease, which affects mainly young adults, may debut at any age. The rarity and clinical curiosity of this entity suggested reporting of my patient’s case. Evidence-based up-to-date information on Crohn’s disease is also documented.
Literature
1.
go back to reference Emory TS, Sobin LH. Idiopathic inflammatory bowel disease. In: Iacobuzio-Donahue CA, Montgomery EA, editors. Gastrointestinal and liver pathology. 2nd ed. Philadelphia: Elsevier Saunders; 2012. p. 352–366. Emory TS, Sobin LH. Idiopathic inflammatory bowel disease. In: Iacobuzio-Donahue CA, Montgomery EA, editors. Gastrointestinal and liver pathology. 2nd ed. Philadelphia: Elsevier Saunders; 2012. p. 352–366.
2.
go back to reference Dalziel TK. Chronic interstitial enteritis. Br Med J. 1913;2:1068. Dalziel TK. Chronic interstitial enteritis. Br Med J. 1913;2:1068.
3.
go back to reference Lockhart-Mummery HE, Morson BC. Crohn’s disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut. 1960;1:87. Lockhart-Mummery HE, Morson BC. Crohn’s disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut. 1960;1:87.
4.
go back to reference Morson BC, Lockhart-Mummery HE. Anal lesions in Crohn’s disease. Lancet. 1959;2:1122. Morson BC, Lockhart-Mummery HE. Anal lesions in Crohn’s disease. Lancet. 1959;2:1122.
5.
go back to reference Fielding JF, Toye DK, Beton DK, Cooke WT. Crohn’s disease of the stomach and duodenum. Gut. 1970;11:1001. Fielding JF, Toye DK, Beton DK, Cooke WT. Crohn’s disease of the stomach and duodenum. Gut. 1970;11:1001.
6.
go back to reference Basu MK, Asquith P, Thompson RA, Cooke WT. Proceedings: Oral lesions in patients with Crohn’s disease. Gut. 1974;15:346. Basu MK, Asquith P, Thompson RA, Cooke WT. Proceedings: Oral lesions in patients with Crohn’s disease. Gut. 1974;15:346.
7.
go back to reference Huchzermeyer H, Paul F, Seifert E, Frohlich H, Rasmussen CW. Endoscopic results in five patients with Crohn’s disease of the esophagus. Endoscopy. 1977;8:75. Huchzermeyer H, Paul F, Seifert E, Frohlich H, Rasmussen CW. Endoscopic results in five patients with Crohn’s disease of the esophagus. Endoscopy. 1977;8:75.
8.
go back to reference Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn’s Disease Study: extraintestinal manifestations of perianal complications. Gastroenterology. 1979;77:914. Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn’s Disease Study: extraintestinal manifestations of perianal complications. Gastroenterology. 1979;77:914.
9.
go back to reference Greenstein AJ, Sachar DB, Smith H, Janowitz HD, Aufses AH Jr. Patterns of neoplasia in Crohn’s disease and ulcerative colitis. Cancer. 1980;46:403. Greenstein AJ, Sachar DB, Smith H, Janowitz HD, Aufses AH Jr. Patterns of neoplasia in Crohn’s disease and ulcerative colitis. Cancer. 1980;46:403.
10.
go back to reference Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92(7):1088–103. Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92(7):1088–103.
11.
go back to reference Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54. e42; quiz e30 Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54. e42; quiz e30
12.
go back to reference Ng SC, Bernstein CN, Vatn MH, et al. Epidemiology and Natural History Task Force of the International Organization of Inflammatory Bowel Disease (IOIBD). Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013;62(4):630–49. Ng SC, Bernstein CN, Vatn MH, et al. Epidemiology and Natural History Task Force of the International Organization of Inflammatory Bowel Disease (IOIBD). Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013;62(4):630–49.
13.
go back to reference Loftus EV Jr. Clinical epidemiology of inflammatory bowel dis-ease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–17. Loftus EV Jr. Clinical epidemiology of inflammatory bowel dis-ease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–17.
14.
go back to reference Kúsulas-Delint D, González-Regueiro JA, Rodríguez-Aldama JC, García-Miranda FS, García-Santos RA, et al. Crohn’s disease: review and current concepts. Rev Invest Med Sur Mex. 2016;23(1):10–20. Kúsulas-Delint D, González-Regueiro JA, Rodríguez-Aldama JC, García-Miranda FS, García-Santos RA, et al. Crohn’s disease: review and current concepts. Rev Invest Med Sur Mex. 2016;23(1):10–20.
15.
go back to reference Schultz M, Butt A. Is the north to south gradient in inflammatory bowel disease a global phenomenon? Expert Rev Gastroenterol Hepatol. 2012;6(4):445–7. Schultz M, Butt A. Is the north to south gradient in inflammatory bowel disease a global phenomenon? Expert Rev Gastroenterol Hepatol. 2012;6(4):445–7.
16.
go back to reference Vind I, Riis L, Jess T, Knudsen E. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101(6):1274–82. Vind I, Riis L, Jess T, Knudsen E. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101(6):1274–82.
17.
go back to reference Yapp T, Stenson R, Thomas G. Crohn’s disease incidence in Cardiff from 1930: an update for 1991-1995. Eur J Gastroenterol Hepatol. 2000;12(8):907–11. Yapp T, Stenson R, Thomas G. Crohn’s disease incidence in Cardiff from 1930: an update for 1991-1995. Eur J Gastroenterol Hepatol. 2000;12(8):907–11.
18.
go back to reference Rubin G, Hungin A, Kelly P. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther. 2000;14(12):1553–9. Rubin G, Hungin A, Kelly P. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther. 2000;14(12):1553–9.
19.
go back to reference Loftus C, Loftus E, Harmsen S. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13(3):254–61. Loftus C, Loftus E, Harmsen S. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13(3):254–61.
20.
go back to reference Bernstein C, Wajda A, Svenson L. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol. 2006;101(7):1559–68. Bernstein C, Wajda A, Svenson L. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol. 2006;101(7):1559–68.
21.
go back to reference Cosnes J, Gower-Rousseau C, Seksik P. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94. Cosnes J, Gower-Rousseau C, Seksik P. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94.
22.
go back to reference Hou J, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol. 2009;104(8):2100–9. Hou J, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol. 2009;104(8):2100–9.
23.
go back to reference Yamamoto-Furusho J. Clinical epidemiology of ulcerative colitis in Mexico. J Clin Gastroenterol. 2009;43(3):221–4. Yamamoto-Furusho J. Clinical epidemiology of ulcerative colitis in Mexico. J Clin Gastroenterol. 2009;43(3):221–4.
24.
go back to reference Cho KJ, Suh YL, Kim CW, Chi JG. Crohn’s disease - a case report. J Korean Med Sci. 1987;2(2):133–6. Cho KJ, Suh YL, Kim CW, Chi JG. Crohn’s disease - a case report. J Korean Med Sci. 1987;2(2):133–6.
25.
go back to reference Logan I, Bowlus CL. The geoepidemiology of autoimmune intestinal disease. Autoimmun Rev. 2013;9(5):A372–8. Logan I, Bowlus CL. The geoepidemiology of autoimmune intestinal disease. Autoimmun Rev. 2013;9(5):A372–8.
26.
go back to reference Monstad I, Hovde O, Solberg IC, A Moum B. Clinical course and prognosis in ulcerative colitis: results from population based and observational studies. Annals of Gastroenterology. 2014;27:95-104. Monstad I, Hovde O, Solberg IC, A Moum B. Clinical course and prognosis in ulcerative colitis: results from population based and observational studies. Annals of Gastroenterology. 2014;27:95-104.
27.
go back to reference Economou M, Zambeli E, Michopoulos S. Incidence and prevalence of Crohn’s disease and its etiological influence. Ann Gastroenterol. 2009;22(3):58–67. Economou M, Zambeli E, Michopoulos S. Incidence and prevalence of Crohn’s disease and its etiological influence. Ann Gastroenterol. 2009;22(3):58–67.
28.
go back to reference Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96(3):635–43. Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96(3):635–43.
29.
go back to reference Sathiyasekaran M, Shivbalan S. Crohn’s disease. Indian J Pediatr. 2006;73(8):723–9. Sathiyasekaran M, Shivbalan S. Crohn’s disease. Indian J Pediatr. 2006;73(8):723–9.
30.
go back to reference Ouyang Q, Tandon R, Goh KL, et al. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21:408–13. Ouyang Q, Tandon R, Goh KL, et al. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21:408–13.
31.
go back to reference Wright JP, Froggatt J, O’Keefe EA, et al. The epidemiology of inflammatory bowel disease in Cape Town 1980–1984. S Afr Med J. 1996;70:10–5. Wright JP, Froggatt J, O’Keefe EA, et al. The epidemiology of inflammatory bowel disease in Cape Town 1980–1984. S Afr Med J. 1996;70:10–5.
32.
go back to reference Lakatos PL. Recent trends in the epidemiology of inflammatory bowel disease: up or down. World J Gastroenterol. 2006;14:6102–8. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel disease: up or down. World J Gastroenterol. 2006;14:6102–8.
33.
go back to reference Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn’s disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther. 2007;25:1373–88. Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn’s disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther. 2007;25:1373–88.
34.
go back to reference Steury EM, Templeton AC. Crohn’s disease in Africa: a case report and review. Trop Geogr Med. 1980;32(2):172–3. Steury EM, Templeton AC. Crohn’s disease in Africa: a case report and review. Trop Geogr Med. 1980;32(2):172–3.
35.
go back to reference Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African-Americans, Hispanics, and non-Hispanic whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012–23. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African-Americans, Hispanics, and non-Hispanic whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012–23.
36.
go back to reference Mulhall AM, Gholson RD, Eichenberger MR, Galandiuk S. Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis. 2008;14(7):960–7. Mulhall AM, Gholson RD, Eichenberger MR, Galandiuk S. Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis. 2008;14(7):960–7.
37.
go back to reference Behzadi P, Behzadi E, Ranjbar R. The incidence and prevalence of Crohn’s disease in global scale. SOJ Immunol. 2015;3(2):1–6. Behzadi P, Behzadi E, Ranjbar R. The incidence and prevalence of Crohn’s disease in global scale. SOJ Immunol. 2015;3(2):1–6.
38.
go back to reference Platell C, Mackay J, Collopy B, et al. Anal pathology in patients with Crohn’s disease. Aust N Z J Surg. 1996;66:5–9. Platell C, Mackay J, Collopy B, et al. Anal pathology in patients with Crohn’s disease. Aust N Z J Surg. 1996;66:5–9.
39.
go back to reference Thompson NP, Wakefield AJ, Pounder RE. Prognosis and prognostic factors in inflammatory bowel disease. Saudi J Gastroentrol. 1995;1(3):129–37. Thompson NP, Wakefield AJ, Pounder RE. Prognosis and prognostic factors in inflammatory bowel disease. Saudi J Gastroentrol. 1995;1(3):129–37.
40.
go back to reference Freeman HJ. Use of the Crohn’s disease activity index in clinical trials of biological agents. World J Gastroenterol. 2008;14(26):4127–30. Freeman HJ. Use of the Crohn’s disease activity index in clinical trials of biological agents. World J Gastroenterol. 2008;14(26):4127–30.
41.
go back to reference Cheifetz AS. Management of active Crohn disease. JAMA. 2013;309(20):2150–8. Cheifetz AS. Management of active Crohn disease. JAMA. 2013;309(20):2150–8.
42.
go back to reference Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut. 2006;55:1–15. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut. 2006;55:1–15.
43.
go back to reference Dambha F, Tanner J, Carroll N. Diagnostic imaging in Crohn’s disease: what is the new gold standard? Best Pract Res Clin Gastroenterol. 2014;28(3):421–36. Dambha F, Tanner J, Carroll N. Diagnostic imaging in Crohn’s disease: what is the new gold standard? Best Pract Res Clin Gastroenterol. 2014;28(3):421–36.
44.
go back to reference Harbord M, Annese V, Vavricka SR, European Crohn’s and Colitis Organization, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239–54. Harbord M, Annese V, Vavricka SR, European Crohn’s and Colitis Organization, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239–54.
45.
go back to reference Williams H, Walker D, Orchard TR. Extra-intestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2008;10(6):597–605. Williams H, Walker D, Orchard TR. Extra-intestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2008;10(6):597–605.
46.
go back to reference Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20(3):451–71. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20(3):451–71.
47.
go back to reference Wordsworth P. Arthritis and inflammatory bowel disease. Curr Rheumatol Rep. 2000;2(2):87–8. Wordsworth P. Arthritis and inflammatory bowel disease. Curr Rheumatol Rep. 2000;2(2):87–8.
48.
go back to reference Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α-biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145(6):1464–78. e5 Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α-biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145(6):1464–78. e5
49.
go back to reference Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B. Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Hospitalizations and surgery in Crohn’s disease. Gut. 2012;61(4):622–9. Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B. Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Hospitalizations and surgery in Crohn’s disease. Gut. 2012;61(4):622–9.
50.
go back to reference Gomollón F, Dignass A, Annese V, et al. ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016, part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3–25. Gomollón F, Dignass A, Annese V, et al. ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016, part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3–25.
51.
go back to reference Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther. 2006;28(12):1983–8. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther. 2006;28(12):1983–8.
52.
go back to reference Cosnes J, Bourrier A, Laharie D, Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID), et al. Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758–65. e2; quiz e14–5. Cosnes J, Bourrier A, Laharie D, Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID), et al. Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758–65. e2; quiz e14–5.
53.
go back to reference Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;10:CD000067. Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;10:CD000067.
54.
go back to reference Panés J, López-Sanromán A, Bermejo F, AZTEC Study Group, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145(4):766–74. e1 Panés J, López-Sanromán A, Bermejo F, AZTEC Study Group, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145(4):766–74. e1
55.
go back to reference Sandborn WJ, Colombel JF, Enns R, International Efficacy of Natalizumab as Active Crohn’s Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–25. Sandborn WJ, Colombel JF, Enns R, International Efficacy of Natalizumab as Active Crohn’s Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–25.
56.
go back to reference Van Assche G, Van Ranst M, Sciot R, et al. Progressive multi-focal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353(4):362–8. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multi-focal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353(4):362–8.
57.
go back to reference Sandborn WJ, Feagan BG, Rutgeerts P, GEMINI 2 Study Group, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21. Sandborn WJ, Feagan BG, Rutgeerts P, GEMINI 2 Study Group, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21.
58.
go back to reference Sandborn WJ, Gasink C, Gao LL, CERTIFI Study Group, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–28. Sandborn WJ, Gasink C, Gao LL, CERTIFI Study Group, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–28.
59.
go back to reference Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(6):674–88. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(6):674–88.
60.
go back to reference Katsanos KH, Tsianos VE, Maliouki M, et al. Obstruction and pseudo-obstruction in inflammatory bowel disease. Ann Gastroenterol. 2010;23(4):243–56. Katsanos KH, Tsianos VE, Maliouki M, et al. Obstruction and pseudo-obstruction in inflammatory bowel disease. Ann Gastroenterol. 2010;23(4):243–56.
61.
go back to reference Louis E, Collard A, Oger AF. Behavior of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777–82. Louis E, Collard A, Oger AF. Behavior of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777–82.
Metadata
Title
Crohn’s disease in a developing African mission hospital: a case report
Author
Bamidele Johnson Alegbeleye
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2019
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-019-1971-5

Other articles of this Issue 1/2019

Journal of Medical Case Reports 1/2019 Go to the issue